Saturday, January 29, 2022 9:31:47 PM
Hank,
Given the fact that most control patients had also crossed over, even though blinded as to who had what treatment, it would have been pretty clear that lots of people were living longer than anticipated for the SOC alone. The trial is officially blinded until you know what treatment each patient received, that didn't occur until the trial was data locked, but data, like what Dr. Liau reported on the Top 100 at SNO in 2019 should be easy to see that many in the trial were living 5 years or more, far more than would have been the case with all on the SOC.
There were really not many patients in the trial that didn't cross over. It's just speculation by me, but I believe those who didn't either passed away, or were to sick to do so, by the time they had the opportunity to do so. If I'm right, virtually no patients will be among those who're still alive that didn't receive the vaccine either up front or on crossing over.
Gary
Given the fact that most control patients had also crossed over, even though blinded as to who had what treatment, it would have been pretty clear that lots of people were living longer than anticipated for the SOC alone. The trial is officially blinded until you know what treatment each patient received, that didn't occur until the trial was data locked, but data, like what Dr. Liau reported on the Top 100 at SNO in 2019 should be easy to see that many in the trial were living 5 years or more, far more than would have been the case with all on the SOC.
There were really not many patients in the trial that didn't cross over. It's just speculation by me, but I believe those who didn't either passed away, or were to sick to do so, by the time they had the opportunity to do so. If I'm right, virtually no patients will be among those who're still alive that didn't receive the vaccine either up front or on crossing over.
Gary
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
